Sabby Management’s Halozyme HALO Stock Holding History

Sabby Management’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-532	Closed	-$526K	–	278
2016 Q4	$526K	Buy	+532	New	+$5.83K	0.03%	192
2016 Q1	–	Sell	-840	Closed	-$1.46M	–	317
2015 Q4	$1.46M	Hold	840	–	–	0.08%	152
2015 Q3	$1.13M	Hold	840	–	–	0.05%	221
2015 Q2	$1.9M	Buy	840 +638	+316%	+$11.2K	0.07%	167
2015 Q1	$288K	Buy	+202	New	+$2.91K	0.01%	256

Other funds holding HALO

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sabby Management's HALO Position: Q2 2018 in Review

Sabby Management sold out of Halozyme (HALO) in Q2 2018, closing a stake of 102 shares — an estimated $2K sold.

Sabby Management first reported a position in HALO in Q1 2015 and held it in 3 quarters. The position peaked at $2.74M in Q1 2015. 193 funds tracked by Wall St. Rank hold HALO as of Q2 2018.

Sabby Management reported no remaining Halozyme position as of Q2 2018 after selling out during the quarter.
Sabby Management sold 102 Halozyme shares in Q2 2018, an estimated $2K.
Sabby Management first reported a position in Halozyme in Q1 2015 and held it in 3 quarters.
Sabby Management's Halozyme position peaked at $2.74M in Q1 2015.
193 funds tracked by Wall St. Rank held Halozyme as of Q2 2018.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.